Johnson & Johnson Quarterly Income Statement
NYSE: JNJHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Johnson & Johnson revenue and earnings
In the quarter ended Jun 28, 2026, Johnson & Johnson generated $25.31 billion in revenue, up 6.6% from the same quarter a year earlier. Net income was $5.53 billion (-0.1% year over year), for a net margin of 21.9% versus a median of 21.8% in the prior 5 quarters. Gross margin was 68.2% (up from 67.9%).
Diluted earnings per share came in at $2.27, down from $2.29.
Summary generated from market data by MetaCap's automated system. Methodology
Johnson & Johnson income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-28 | Q1 20262026-03-29 | Q4 20252025-12-28 | Q3 20252025-09-28 | Q2 20252025-06-29 | Q1 20252025-03-30 | Q4 20242024-12-29 | Q3 20242024-09-29 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-10-01 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.31B | 24.06B | 24.56B | 23.99B | 23.74B | 21.89B | 22.52B | 22.47B | 22.45B | 21.38B | 21.39B | 21.35B |
| Revenue growth (YoY) | +6.60% | +9.91% | +9.08% | +6.77% | +5.77% | +2.39% | +5.26% | +5.25% | +4.31% | +2.34% | +7.30% | +6.78% |
| Cost of Revenue | 8.05B | 8.11B | 7.97B | 7.30B | 7.63B | 7.36B | 7.13B | 6.96B | 6.87B | 6.51B | 6.80B | 6.61B |
| Gross Profit | 17.26B | 15.96B | 16.60B | 16.69B | 16.11B | 14.54B | 15.39B | 15.51B | 15.58B | 14.87B | 14.60B | 14.74B |
| Research & Development | 3.65B | 3.53B | 4.25B | 3.67B | 3.52B | 3.23B | 5.30B | 4.95B | 3.44B | 3.54B | 4.48B | 3.45B |
| Selling, General & Admin | 6.43B | 6.03B | 6.75B | 5.92B | 5.89B | 5.11B | 6.45B | 5.48B | 5.68B | 5.26B | 5.81B | 5.40B |
| Interest Expense | 281.00M | 272.00M | 214.00M | 245.00M | 308.00M | 204.00M | 137.00M | 193.00M | 270.00M | 155.00M | 151.00M | 192.00M |
| Other Income (Expense) | -331.00M | -294.00M | -483.00M | 478.00M | -107.00M | 7.32B | 161.00M | -1.80B | -653.00M | -2.40B | 421.00M | -499.00M |
| Pretax Income | 6.75B | 5.99B | 4.97B | 7.49B | 6.49B | 13.63B | 3.89B | 3.34B | 5.75B | 3.71B | 4.83B | 5.22B |
| Income Tax | 1.21B | 755.00M | -150.00M | 2.34B | 954.00M | 2.63B | 456.00M | 644.00M | 1.06B | 459.00M | 694.00M | 908.00M |
| Net Income | 5.53B | 5.24B | 5.12B | 5.15B | 5.54B | 11.00B | 3.43B | 2.69B | 4.69B | 3.25B | 4.05B | 26.03B |
| Net Income growth (YoY) | -0.05% | -52.40% | +49.11% | +91.24% | +18.16% | +237.91% | -15.26% | -89.65% | -8.90% | — | +15.03% | +483.85% |
| EPS (Basic) | 2.30 | 2.17 | 2.12 | 2.14 | 2.30 | 4.57 | 1.42 | 1.12 | 1.95 | 1.35 | 1.68 | 10.32 |
| EPS (Diluted) | 2.27 | 2.14 | 2.08 | 2.12 | 2.29 | 4.54 | 1.41 | 1.11 | 1.93 | 1.34 | 1.67 | 10.21 |
| Shares Outstanding (Basic) | 2.41B | 2.41B | — | 2.41B | 2.41B | 2.41B | — | 2.41B | 2.41B | 2.41B | — | 2.52B |
| Shares Outstanding (Diluted) | 2.44B | 2.45B | — | 2.43B | 2.42B | 2.42B | — | 2.43B | 2.42B | 2.43B | — | 2.55B |
| Gross Margin | 68.19% | 66.31% | 67.56% | 69.56% | 67.87% | 66.40% | 68.35% | 69.01% | 69.40% | 69.55% | 68.23% | 69.06% |
| Net Margin | 21.86% | 21.76% | 20.83% | 21.47% | 23.32% | 50.24% | 15.24% | 11.99% | 20.88% | 15.22% | 18.92% | 121.91% |
This table shows 12 quarterly periods of Johnson & Johnson's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow JNJ's reporting calendar. What is a income statement?